157 related articles for article (PubMed ID: 30260898)
21. Clinical outcomes of low-dose and high-dose postoperative radioiodine therapy in patients with intermediate-risk differentiated thyroid cancer.
Jeong JH; Kong EJ; Jeong SY; Lee SW; Cho IH; Ah Chun K; Lee J; Ahn BC
Nucl Med Commun; 2017 Mar; 38(3):228-233. PubMed ID: 27984538
[TBL] [Abstract][Full Text] [Related]
22. Lung Metastasis in Children with Differentiated Thyroid Cancer: Factors Associated with Diagnosis and Outcomes of Therapy.
Chesover AD; Vali R; Hemmati SH; Wasserman JD
Thyroid; 2021 Jan; 31(1):50-60. PubMed ID: 32517539
[No Abstract] [Full Text] [Related]
23. Molecular technology and the recombinant TSH have changed diagnostics of thyroid carcinoma with positive I-131 whole body scan but low serum thyroglobulin.
Montella L; Caraglia M; Abbruzzese A; Soricelli A; Prete SD; Squame G; Salvatore M
Exp Mol Med; 2004 Jun; 36(3):268-73. PubMed ID: 15272239
[TBL] [Abstract][Full Text] [Related]
24. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.
Maruoka Y; Abe K; Baba S; Isoda T; Sawamoto H; Tanabe Y; Sasaki M; Honda H
Radiology; 2012 Dec; 265(3):902-9. PubMed ID: 23012466
[TBL] [Abstract][Full Text] [Related]
25. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
26. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
[TBL] [Abstract][Full Text] [Related]
27. Differentiated thyroid carcinoma: Incremental diagnostic value of
Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
[TBL] [Abstract][Full Text] [Related]
28. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of radioiodine therapy in differentiated thyroid cancer subjects with elevated serum thyroglobulin and negative whole body scan using 131I with emphasize on the thallium scintigraphy in these subgroups.
Zakani A; Saghari M; Eftekhari M; Fard-Esfahani A; Fallahi B; Esmaili J; Assadi M
Eur Rev Med Pharmacol Sci; 2011 Oct; 15(10):1215-21. PubMed ID: 22165686
[TBL] [Abstract][Full Text] [Related]
30. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function.
Tuttle RM; Lopez N; Leboeuf R; Minkowitz SM; Grewal R; Brokhin M; Omry G; Larson S
Thyroid; 2010 Mar; 20(3):257-63. PubMed ID: 20187781
[TBL] [Abstract][Full Text] [Related]
31. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
Lind P; Gallowitsch HJ
Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
[TBL] [Abstract][Full Text] [Related]
32. Usefulness of (99m)Tc-pertechnetate whole body scan with neck and chest SPECT/CT for detection of post-surgical thyroid remnant and metastasis in differentiated thyroid cancer patients.
Chantadisai M; Kingpetch K
Ann Nucl Med; 2014 Aug; 28(7):674-82. PubMed ID: 24889127
[TBL] [Abstract][Full Text] [Related]
33. Predictive factors for the outcomes of initial I-131 low-dose ablation therapy to Japanese patients with differentiated thyroid cancer.
Ito S; Iwano S; Kato K; Naganawa S
Ann Nucl Med; 2018 Jul; 32(6):418-424. PubMed ID: 29766463
[TBL] [Abstract][Full Text] [Related]
34. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
[TBL] [Abstract][Full Text] [Related]
35. The Value of Pre-Ablative I-131 Scan for Clinical Management in Patients With Differentiated Thyroid Carcinoma.
van der Boom T; Zandee WT; Dekkers CCJ; van der Horst-Schrivers ANA; Jansen L; Kruijff S; Brouwers AH; Links TP
Front Endocrinol (Lausanne); 2021; 12():655676. PubMed ID: 34122334
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity of preparation with rhTSH or thyroid hormone withdrawal using ¹³¹I-whole body scans to identify metastases of differentiated thyroid cancer.
Liepe K
Int J Surg; 2015 Apr; 16(Pt A):107-112. PubMed ID: 25771100
[TBL] [Abstract][Full Text] [Related]
37. Thyroid Remnant Estimation by Diagnostic Dose (131)I Scintigraphy or (99m)TcO4(-) Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose (131)I Imaging.
Liu G; Li N; Li X; Chen S; Du B; Li Y
Biomed Res Int; 2016; 2016():4763824. PubMed ID: 27034938
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low-risk differentiated thyroid cancer.
Albano D; Bonacina M; Durmo R; Bertagna F; Giubbini R
Endocrine; 2020 Apr; 68(1):124-131. PubMed ID: 31784881
[TBL] [Abstract][Full Text] [Related]
39. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
Pacini F; Molinaro E; Castagna MG; Agate L; Elisei R; Ceccarelli C; Lippi F; Taddei D; Grasso L; Pinchera A
J Clin Endocrinol Metab; 2003 Aug; 88(8):3668-73. PubMed ID: 12915653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]